Development of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.03796-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Vasu Saini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Phase Scientific International Ltd., Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Uterine Cervical Dysplasia, Papillomavirus Infections, Uterine Cervical Neoplasms, Polymerase Chain Reaction. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study evaluated and optimized a novel urine-based workflow using high-risk human papillomavirus (hrHPV) polymerase chain reaction (PCR) test to detect 14 hrHPV genotypes linked to cervical intraepithelial neoplasia (CIN) abnormalities for cervical cancer screening. In cohort 1 for clinical feasibility, 82 women with confirmed CIN2+ abnormalities provided paired urine and cervical brush samples before treatment. Urine was tested with the novel hrHPV workflow, and cervical brushes with the Cobas HPV Test (Roche). For Ct cut-off optimization in cohort 2, urine samples from 983 women in a primary screening, triage, and follow-up program were analyzed, optimizing CIN2+ and CIN3+ sensitivity and specificity by varying the 12-other hrHPV channel Ct cut-off from 28.0 to 38.0, while maintaining HPV16/18 Ct cut-offs at 38.0. In cohort 1, the urine hrHPV test showed 92.7% sensitivity for CIN2+ and 93.9% for CIN3+, exceeding cervical brush sensitivities of 78.1% and 90.9%, respectively. In cohort 2, the 12-other hrHPV Ct altered CIN2+ sensitivity from 76.6% to 93.6% and specificity from 83.1% to 75%. ROC analysis identified optimal cut-offs at 32.76 for CIN2+ and 30.47 for CIN3+. The proposed cut-offs are HPV16/18 at 38.0, and 12 other hrHPV at 33.0 for maximum sensitivity (93.62% CIN2+, 90.91% CIN3+) or at 30.5 for balanced performance (89.36% CIN2+ sensitivity, 80% specificity). The urine-based hrHPV test uses 40 mL of urine collected using a standard urine collection device, and demonstrated high sensitivity for CIN2+ prediction. Adjustable Ct thresholds allow tailored performance optimization, thereby enhancing accessibility, adherence, and early cervical cancer detection across diverse clinical settings. IMPORTANCE A novel urine-based high-risk human papillomavirus (hrHPV) polymerase chain reaction test was developed to detect 14 hrHPV genotypes, including individual HPV16 and HPV18 typing, associated with cervical cancer progression. By employing a liquid-liquid separation method to extract DNA from large-volume (40 mL) pot-collected urine samples, the test demonstrated sensitivities of 92.7% for cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and 93.9% for CIN3+. Optimization of cycle threshold cut-offs yielded 93% sensitivity and 77% specificity for predicting CIN2+ in an enriched population. It can enhance accessibility, compliance, and early detection across diverse clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase Scientific International Ltd., Hong Kong, Hong Kong.
- Peking University Shenzhen Hospital, Shenzhen, China.
ORCID-Profile: Vasu Saini, Zhengyang Guo, Jinwen Yu, Peng Yin, Garrett Lee Mosley, Wenkui Dai, Ricky Yin To Chiu
Zitieren
APA
Saini, V., Guo, Z., Yu, J., Wu, D., Du, H., Yin, P., Mosley, G. L., Dai, W., & Chiu, R. Y. T. (2026). Development of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03796-25
Vancouver
Saini V, Guo Z, Yu J, Wu D, Du H, Yin P, et al. Development of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer. Microbiology Spectrum. 2026. doi:10.1128/spectrum.03796-25
BibTeX
@article{Saini2026,
author = {Saini, Vasu and Guo, Zhengyang and Yu, Jinwen and Wu, Di and Du, Hui and Yin, Peng and Mosley, Garrett Lee and Dai, Wenkui and Chiu, Ricky Yin To},
title = {Development of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.03796-25}
}
EUVIMED